Our Commercial Manager of the Clinical Analysis division, Sofía Lazaneo, participated in the annual meeting of representatives of Binding Site in Latin America and had the honor of presenting Uruguay as a Success Case in the region for the adoption of Freelite in our country.
Freelite is an automated assay that measures free light chains and provides the highest possible diagnostic sensitivity for multiple myeloma. Thus, it allows patients to access early detection, one of the most important factors according to GELAMM.
Proud to contribute to the health of thousands of Uruguayans, we hope to continue growing on this path.
